NCT03376503View on ClinicalTrials.gov

Nanogen Pegfilgrastim (Pegcyte) PK/PD Clinical Study in Breast Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 25, 2016

Primary Completion Date

October 9, 2017

Study Completion Date

November 6, 2017

Conditions
Breast Cancer
Interventions
DRUG

Pegfilgrastim

PK,PD and safety assessment

Trial Locations (1)

Unknown

Vietnam National Cancer Institute (Hospital K), Hanoi

Sponsors
All Listed Sponsors
lead

Nanogen Pharmaceutical Biotechnology Joint Stock Company

INDUSTRY

NCT03376503 - Nanogen Pegfilgrastim (Pegcyte) PK/PD Clinical Study in Breast Cancer Patients | Biotech Hunter | Biotech Hunter